1. Report Overview

1.1 Global Generic Drugs: Market Overview

1.2 Global Generic Drugs Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is this Report for?

1.7 Methodology

1.8 Frequently Asked Questions (FAQs)

1.9 Associated Visiongain Reports

1.10 About Visiongain

2. An Introduction to Generic Drugs

2.1 An Introduction to the Rise of Generic Drugs

2.2 What Are Generic Drugs?

2.2.1 Generic Active Ingredients

2.3 A Brief Overview of the Pharmaceutical Industry

2.3.1 Brief History of Generic Drugs

2.3.2 The Hatch-Waxman Act: The Rise of Generics

2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics

2.5 Types of Generics – Authorised, Branded and Unbranded

2.6 Complex Generics

2.7 Classification of Generic Drugs Markets

2.8 Is Generic Substitution Bad News for Big Pharma Business?

2.8.1 The 'Ever greening' of Pharmaceutical Products

2.9 Regulation of Generic Drugs

2.9.1 Regulation in the US

2.9.1.1 Obtaining FDA Approval: NDAs and ANDAs

2.9.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs

2.9.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry

2.9.1.4 How Has the Hatch-Waxman Act Impacted upon the US Pharmaceutical Market?

2.9.1.5 How the Timing of Market Entry Influences Product Success

2.9.2 Regulation in Europe

2.9.2.1 EU Marketing Approval Procedures

2.9.2.2 The 8+2+1 Rule: EU Data Exclusivity

2.9.2.3 Supplementary Protection Certificates

2.9.2.4 Variation in Drug Development Regulations between European Countries

2.9.2.5 The Move towards the Harmonisation of Standards

2.9.2.6 The Impact of Europe’s Unitary Patent System on Generic Drugs

2.9.2.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing

2.9.3 Regulation in Japan

2.9.4 Regulation in China

2.10 Compulsory Licensing

2.11 Market Definition and Scope of This Report

2.11.1 Market Sizing and Revenue Reporting

3. Generic Drugs Market 2017-2028

3.1 The Global Generic Drugs Market: Market Overview

3.1.1 Segmenting the Global Generic Drugs Market

3.2 The Rise of the Global Generic Drugs Market in 2018

3.3 The Global Generic Drugs Market: Sales Forecast 2017-2028

3.4 Generic Drugs: Regional Market Forecast: 2017-2028

3.4.1 Changes in Generic Drug Regional Market Shares 2017-2028

3.5 National Markets That Will Drive Generic Drugs Growth

3.6 Changes in Market Shares by National Market 2017-2028

3.7 Drivers and Restraints for the Global Generic Drugs Market 2017-2028

4. North America Generic Drugs Market, 2017-2028

4.1 Generic Drugs in the North America: Market Overview

4.1.1 The Hatch-Waxman Act and Its Ongoing Effects

4.1.2 Consolidation in the Drug Development and Supply Chain Driving North America Generics

4.2 North America Generic Drugs Market: Drivers and Restraints 2017-2028

4.3 North America Generic Drugs Market Forecast: 2017-2028

4.4 Leading Companies Operating within the North America Generic Drugs Market

4.4.1 Increasing Acceptance of Generics amongst Consumers

4.4.2 Affordable Care Act: Expanding Medicare Coverage

4.5 North America Generic Drugs Market – Strategic Analysis

4.5.1 Will Biosimilars Dictate the Future of the US Generics Market?

4.5.2 The Backlog of ANDA Applications

4.5.3 The Generic Drug User Fee Amendments (GDUFA)

4.5.4 Shortages of Generic Drugs Will Restrain the Market

4.5.5 The Anti-Competitive ‘Pay for Delay’ Effect

4.6 US Generic Drugs Market: A Range of Factors Contributing to Growth

4.7 Canada Generic Drugs Market: A Range of Factors Contributing to Growth

4.8 North America Generic Drugs Market: Market Share Analysis

5. Europe Generic Drugs Market, 2017-2028

5.1 Generic Drugs in the Europe: Market Overview

5.1.1 Why Growth in Some Markets is Being Hindered?

5.1.2 Predominant Pricing Systems and Generic Penetration in European Markets

5.1.2.1 Lower Patient Co-Payments Drive Demand for Generics

5.1.2.2 The Effects of Tendering for Generic Medicines

5.1.3 Will Europe Move towards Free-Pricing Systems?

5.1.4 Challenges in the European Regulatory Environment

5.1.5 Ending Anti-Competitive ‘Pay for Delay’ Tactics in Europe

5.1.6 FDA and EMA Joint Data Sharing and Inspections

5.2 Europe Generic Drugs Market Forecast: 2017-2028

5.3 Germany Generic Drugs Market: New Reforms to Medicinal Pricing May Impact Market Entry

5.4 UK Generic Drugs Market: A Mature Market with Growth Potentials

5.4.1 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration

5.5 France Generic Drugs Market: Healthcare Reforms Impacting on Market Growth

5.6 Italy Generic Drugs Market: Branded Generics Hindering Overall Growth

5.6.1 The Tightening of Italy’s Patent Legislations

5.6.2 The Italian Healthcare System – A Tale of Falling Budgets

5.7 Spain Generic Drugs Market: Room for Growth

5.7.1 Cost-Containment Measures Helping to Boost Generic Drug Use

5.8 Europe Generic Drugs Market: Market Share Analysis

6. Asia-Pacific Generic Drugs Market, 2017-2028

6.1 Generic Drugs in the Asia-Pacific Market: Market Overview

6.2 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth

6.2.1 Leading Companies in the Indian Generic Drugs Market

6.2.2 Indian Generic Drugs Market: Sales Forecast 2017-2028

6.2.3 The Reforms to India’s Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues

6.2.4 Expansion of the National Healthcare Coverage Increases the Need for Generics

6.2.5 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?

6.3 Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape

6.3.1 The Major Drivers of Growth in the Chinese Generics Market

6.3.2 Chinese Generic Drugs Market: Sales Forecast 2017-2028

6.3.3 Compulsory Licensing of Generic Drugs

6.3.4 Expansion of Healthcare Coverage and Reimbursement

6.3.5 The Impacts of Price Controls and the Anhui Model

6.4 Japanese Generic Drugs Market: High Barriers to Entry

6.4.1 Public Perception of Generics in Japan

6.4.2 Japanese Generic Drugs Market: Leading Companies

6.4.3 Government Initiatives Driving Generic Penetration

6.4.4 Japanese Attitudes to Generic Drugs

6.4.5 Japanese Generic Drugs Market: Sales Forecast 2017-2028

6.5 Australia Generic Drugs Market: Increased Market Access Supports the Market Growth

6.5.1 Australia Generic Drugs Market: Sales Forecast 2017-2028

6.6 South Korean Generic Drugs Market: Expected to Continue Its Trend of Growth

6.6.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea

6.6.2 KORUS FTA: The Free Trade Agreement between South Korea and the US

6.6.3 The Free Trade Agreement between Korea and the European Union

6.6.4 South Korean Generic Drugs Market: Sales Forecast 2017-2028

6.7 Asia-Pacific Generic Drugs Market: Market Share Analysis

7. Middle-East & Africa Generic Drugs Market, 2017-2028

7.1 Generic Drugs in the Middle-East & Africa Market: Market Overview

7.2 South Africa Generic Drugs Market:

7.2.1 South Africa Generic Drugs Market: Sales Forecast 2017-2028

7.3 Saudi Arabia Generic Drugs Market:

7.3.1 Saudi Arabia Generic Drugs Market: Sales Forecast 2017-2028

7.4 UAE Generic Drugs Market:

7.4.1 UAE Generic Drugs Market: Sales Forecast 2017-2028

7.5 Middle-East & Africa Generic Drugs Market: Market Share Analysis

8. Latin America Generic Drugs Market, 2017-2028

8.1 Generic Drugs in the Latin American Market: Market Overview

8.2 Brazil Generic Drugs Market:

8.2.1 Brazil Generic Drugs Market: Sales Forecast 2017-2028

8.3 Argentina Generic Drugs Market:

8.3.1 Argentina Generic Drugs Market: Sales Forecast 2017-2028

8.4 Mexico Generic Drugs Market:

8.4.1 Mexico Generic Drugs Market: Sales Forecast 2017-2028

8.5 Latin America Generic Drugs Market: Market Share Analysis

9. Leading Companies in the Generic Drugs Market, 2017-2028

9.1 Generic Drugs: Continuous Expansion to Rival

9.1.1 The Leading Companies in the Global Generics Market

9.2 Teva Pharmaceuticals Industries Limited

9.2.1 Teva: Historical Financial and Performance Analysis, 2013-2017

9.2.2 Teva Generic Drugs Sales Forecast 2017-2028

9.2.3 Teva acquired Allergan’s Generic Business Segment – Actavis Generic

9.2.3.1 Further Entry into the Japanese Generics Market

9.2.4 Teva: Generic Drugs Portfolio Analysis

9.2.4.1 High-Value Generics to Drive Teva’s Generics Growth?

9.2.4.2 The Shift towards Innovation

9.2.4.3 Copaxone Leads Teva’s Moving Focus

9.2.4.4 The Threat of Generic Erosion to Teva’s Products

9.2.4.5 Teva: What Future Moves Could We Expect?

9.3 Novartis

9.3.1 Novartis/Sandoz: Historical Financial and Performance Analysis, 2013-2017

9.3.2 Novartis/Sandoz Generic Drugs Sales Forecast 2017-2028

9.3.3 Novartis/Sandoz Generic Drugs Portfolio Analysis, 2017

9.3.3.1 Emphasis on Difficult-to-Manufacture Products

9.3.3.2 What Does the Future Hold for Novartis’ Generic Drugs Business?

9.4 Mylan

9.4.1 Mylan: Historical Financial and Performance Analysis, 2012-2016

9.4.2 Mylan Generic Drugs Sales Forecast 2017-2028

9.4.3 Mylan: Recent Developments

9.4.3.1 Acquisition of Meda AB

9.4.3.2 Acquisition of Abbott’s Generic Business

9.4.3.3 Mylan’s Growth in Manufacturing Capacity

9.4.3.4 Mylan Acquires Rights to GSK’s Advair, Diskus and Seretide

9.4.3.5 The Race to Market Copaxone Generics

9.4.3.6 Strategic Acquisition of Agila Expands Mylan’s Injectables Business

9.4.4 Mylan’s Collaborative Efforts

9.4.4.1 Biosimilar Collaboration with India’s Biocon

9.4.4.2 Biosimilar Collaborations with Momenta

9.4.4.3 What Does the Future Hold for Mylan’s Generic Drugs Business?

9.5 Pfizer

9.5.1 Pfizer: Historical Financial and Performance Analysis, 2012-2016

9.5.2 Pfizer’s Restructuring Strategy

9.5.3 Pfizer’s Done Deal with Hospira

9.5.4 Pfizer Generic Drugs Sales Forecast 2017-2028

9.5.5 Hospira: A Brief Overview of Operations

9.5.6 Hospira: Historical Financial and Performance Analysis 2011-2015

9.5.7 Hospira: Recent Developments

9.5.7.1 Hospira’s Expansion through Strategic Acquisitions

9.5.7.2 Hospira: Manufacturing Concerns and Remediation Efforts

9.5.8 Future Prospects for Pfizer’s Generic Business

9.5.8.1 The Pfizer-Allergan Deal Falls Through

9.5.8.2 Activities of Allergan (Actavis) Prior to Mega-Merger

9.5.8.3 Actavis’ Work on Biosimilars

9.6 Abbott

9.6.1 Abbott: Historical Financial and Performance Analysis, 2014-2016

9.6.2 Abbott Generic Drugs Sales Forecast 2017-2028

9.6.3 Abbott: Recent Developments

9.6.3.1 Abbott acquired St. Jude Medical

9.6.3.2 Abbott after the Spin-Off of AbbVie - The Established Products Business Segment

9.6.3.3 Acquisition of Solvay Pharmaceuticals and Piramal Healthcare Solutions

9.6.3.4 Acquisition of CFR Pharmaceuticals Opens New Markets

9.6.4 What Does the Future Hold for Abbott’s Generic Drugs Business?

9.7 Sun Pharma

9.7.1 Sun Pharma’s Business Areas

9.7.2 Sun Pharma: Historical Financial and Performance Analysis, 2011-2015

9.7.3 Sun Pharma Generic Drugs Sales Forecast 2017-2028

9.7.4 Sun Pharma-Ranbaxy Acquisition

9.8 Aspen

9.8.1 Aspen: Historical Financial and Performance Analysis, 2012-2017

9.8.2 Aspen Generic Sales Forecast 2017-2028

9.8.3 Aspen: Recent Developments

9.8.3.1 Aspen Acquires Merck MSD’s Dutch API Plant

9.8.3.2 Acquisition of GSK’s Anti-Thrombosis Brands

9.8.3.3 Future Outlook for Aspen’s Generic Business

9.9 Fresenius Kabi

9.9.1 Fresenius Kabi: Historical Financial and Performance Analysis, 2011-2015

9.9.2 Fresenius Kabi Generic Drugs Sales Forecast 2017-2028

9.9.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions

9.9.4 Fresenius Kabi’s Joint Venture with PT Soho Global Health

9.9.5 Future Prospects for Fresenius Kabi’s Generics Business

9.10 Sanofi

9.10.1 Sanofi: Historical Financial and Performance Analysis, 2011-2015

9.10.2 Sanofi Generic Sales Forecast 2017-2028

9.10.3 Sanofi’s Response to Lantus Competition

9.10.4 Emerging Market Acquisitions

9.10.5 Future Prospects for Sanofi’s Generics Business

9.11 Dr. Reddy’s Laboratories Limited

9.11.1 Dr. Reddy’s: Historical Financial and Performance Analysis, 2015-2017

9.11.2 Dr. Reddy’s Generic Sales Forecast 2017-2028

9.11.3 Dr. Reddy’s launched generic Azacitidine for Injection in the Canadian Market

9.11.4 The company acquired Imperial Credit Private Limited, a Non-Banking Finance Company

9.11.5 Dr. Reddy’s expanded its operations in the European region

9.12 Apotex, Inc.

9.12.1 Apotex expanded its manufacturing facilities in the U.S.

9.12.2 Apotex launched first Generic Version of Merck's Nasonex

10. Qualitative Analysis of the Generic Drugs Market, 2017-2028

10.1 Market Factors Influencing the Global Generic Drugs Market

10.2 SWOT Analysis of the Global Generic Drugs Market, 2017-2028

10.2.1 Strengths

10.2.1.1 Improving Clarity around Regulatory Processes

10.2.1.2 The Continuous Government Support for Generic Manufacturers – Precursors for Innovation

10.2.1.3 Higher Pace of Growth Compared with Innovative Pharma

10.2.1.4 Globalisation and Its Impact on Manufacturing Capabilities

10.2.2 Weaknesses

10.2.2.1 Safety and Quality Concerns in the Manufacturing Process

10.2.2.2 The Non-Uniformity of Excipients

10.2.2.3 The Uncertainty around Patent Extensions and Exclusivities

10.2.2.4 Sceptical Physicians and the Negative Consumer Perception of Generics

10.2.2.5 Inefficiencies in Certain Regulatory Approval Processes

10.2.3 Opportunities

10.2.3.1 Higher Value Biosimilars and Branded Generics

10.2.3.2 Patent Expiries Creating Opportunities

10.2.3.3 Changing Socio-Economic Conditions Impacting Generic Drugs Demand

10.2.3.4 Emerging Markets – Expected to Drive Generics Volume Growth over Time

10.2.4 Threats

10.2.4.1 Government Cost-Cutting Initiatives Impacting on Generic Drugs Prices

10.2.4.2 The Complexity Surrounding Patents and Patent Expiries

10.2.4.3 Pharmacies and Healthcare Payer Consolidations

10.2.4.4 Possible Impacts of a Declining Patent Pool

10.3 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2017-2028

10.3.1 Power of Buyers: Medium

10.3.2 Power of Suppliers: Low

10.3.3 Rivalry among Competitors: High

10.3.4 Threat of New Entrants: High

10.3.5 Threat of Substitutes: Low

11. Conclusions

11.1 Overview of Current Market Conditions and Market Forecast, 2017-2028

11.1 Generic Drugs as a Strategic Tool in Healthcare

11.2 Major Drivers of Growth for Generic Drugs, 2017-2028

11.3 The Regulatory Landscape for Generic Drugs

11.4 Leading Generic Drug Manufacturers

11.5 Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2017-2028

11.6 What Does the Future Hold for the Global Generic Drugs Market?

Appendices

Glossary

Some Associated Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 2.1 Types of Drug Names, 2017

Table 3.1 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Regional and National Markets, 2017 and 2018

Table 3.2 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 3.3 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2017-2028

Table 3.4 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2017, 2022, and 2028

Table 3.5 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2022, 2022-2028, 2017-2028

Table 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2017, 2022, and 2028

Table 4.1 North America Generic Drugs Market: by Country Value ($bn), AGR (%), and CAGR (%), 2017 - 2028

Table 4.2 U.S. Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028

Table 4.3 Canada Generic Drugs Market Value ($bn), AGR (%), CAGR (%), 2017 - 2028

Table 5.1 Europe Generic Drugs Market: by Country Value ($bn), AGR (%) and CAGR (%) 2017 - 2028

Table 5.2 Germany Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028

Table 5.3 UK Generic Drugs Market Value ($bn), AGR (%) and CAGR (%) 2017 - 2028

Table 5.4 France Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028

Table 5.5 Italy Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028

Table 5.6 Spain Generic Drugs Market Value ($bn), AGR (%), and CAGR (%), 2017 - 2028

Table 6.1 India Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 6.2 Leading Drug Types in Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2017, 2022 & 2028

Table 6.3 China Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 6.4 Japan Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 6.5 Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 6.6 South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 7.1 South Africa Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 7.2 Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 7.3 UAE Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 8.1 Brazil Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 8.2 Argentina Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 8.3 Mexico Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.1 Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2016 and 2017

Table 9.2 Teva: Company Overview

Table 9.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Table 9.4 Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.5 Novartis: Overview

Table 9.6 Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Table 9.7 Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.8 Mylan: Company Overview

Table 9.9 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2016

Table 9.10 Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.11 Pfizer: Company Overview

Table 9.12 Pfizer (Greenstone): Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2014-2016

Table 9.13 Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.14 Hospira: Company Overview

Table 9.15 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015

Table 9.16 Abbott: Company Overview

Table 9.17 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2016

Table 9.18 Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.19 Sun Pharmaceuticals: Company Overview

Table 9.20 Sun Pharma: Historical Generic Drugs Sales ($bn), 2013-2017

Table 9.21 Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.22 Aspen: Company Overview

Table 9.23 Aspen: Historical Revenue ($bn, bn Rand) and AGR (%), 2013-2017

Table 9.24 Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.25 Fresenius Kabi: Company Overview

Table 9.26 Fresenius Kabi: Historical Generic Drugs Sales ($bn), 2011-2015

Table 9.27 Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028

Table 9.28 Sanofi: Company Overview

Table 9.29 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015

Table 9.30 Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028

Table 9.31 Dr. Reddy’s Laboratories Limited: Company Overview

Table 9.32 Dr. Reddy’s: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017

Table 9.33 Dr. Reddy’s Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028

Table 9.34 Apotex, Inc.: Company Overview

Table 10.1 SWOT Analysis of the Generic Drugs Market, 2017-2028

Table 11.1 Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2017, 2022 and 2028

Table 11.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2017

Table 11.3 Global Generic Drugs Market Forecast: Revenue ($bn) by Regional Markets, 2017, 2022 and 2028

List of Figures

Figure 1.1 Global Generic Drugs Market Segmentation

Figure 2.1 EU Data Exclusivity for Generics: Possible Scenarios, 2017

Figure 3.1 The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2017

Figure 3.2 The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2018

Figure 3.3 The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2017

Figure 3.4 The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2018

Figure 3.5 Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2017-2028

Figure 3.6 The Global Generic Drugs Market: Market Share (%) by Region, 2017

Figure 3.7 The Global Generic Drugs Market: Market Share (%) by Region, 2022

Figure 3.8 The Global Generic Drugs Market: Market Share (%) by Region, 2028

Figure 3.9 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2022

Figure 3.10 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2022-2028

Figure 3.11 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2028

Figure 3.12 The Global Generic Drugs Market: Market Share (%) by National Markets, 2017

Figure 3.13 The Global Generic Drugs Market: Market Share (%) by National Markets, 2022

Figure 3.14 The Global Generic Drugs Market: Market Share (%) by National Markets, 2028

Figure 3.15 The Global Generic Drugs Market Drivers & Restraints, 2017-2028

Figure 4.1 North America Generic Drugs Market Drivers and Restraints, 2017-2028

Figure 4.2 North America Generic Drugs Market: by Country Value ($bn) and AGR (%) 2017 - 2028

Figure 4.3 U.S. Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 4.4 Canada Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 4.5 North America Generic Drugs Market, % Country Share, 2017

Figure 4.6 North America Generic Drugs Market, % Country Share, 2022

Figure 4.7 North America Generic Drugs Market, % Country Share, 2028

Figure 5.1 Europe Generic Drugs Market: by Country Value ($ bn) and AGR (%) 2017 - 2028

Figure 5.2 Germany Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.3 UK Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.4 France Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.5 Italy Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.6 Spain Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.7 Europe Generic Drugs Market, % Country Share, 2017

Figure 5.8 Europe Generic Drugs Market, % Country Share, 2022

Figure 5.9 Europe Generic Drugs Market, % Country Share, 2028

Figure 6.1 Asia-Pacific Generic Drugs Market Forecast: Revenue ($bn), 2017-2028

Figure 6.2 India Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 6.3 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2017

Figure 6.4 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2022

Figure 6.5 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2028

Figure 6.6 China Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 6.7 Japan Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 6.8 Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2017-2028

Figure 6.9 South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2017-2028

Figure 6.10 Asia-Pacific Generic Drugs Market, % Country Share, 2017

Figure 6.11 Asia-Pacific Generic Drugs Market, % Country Share, 2022

Figure 6.12 Asia-Pacific Generic Drugs Market, % Country Share, 2028

Figure 7.1 Middle-East & Africa Generic Drugs Market Forecast: Revenue ($bn), 2017-2028

Figure 7.2 South Africa Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 7.3 Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 7.4 UAE Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 7.5 Middle-East & Africa Generic Drugs Market, % Country Share, 2017

Figure 7.6 Middle-East & Africa Generic Drugs Market, % Country Share, 2022

Figure 7.7 Middle-East & Africa Generic Drugs Market, % Country Share, 2028

Figure 8.1 Latin America Generic Drugs Market Forecast: Revenue ($bn), 2017-2028

Figure 8.2 Brazil Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 8.3 Argentina Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 8.4 Mexico Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 8.5 Latin America Generic Drugs Market, % Country Share, 2017

Figure 8.6 Latin America Generic Drugs Market, % Country Share, 2022

Figure 8.7 Latin America Generic Drugs Market, % Country Share, 2028

Figure 9.1 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2016

Figure 9.2 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2017

Figure 9.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Figure 9.4 Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.5 Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Figure 9.6 Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.7 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2016

Figure 9.8 Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.9 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2014-2016

Figure 9.10 Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.11 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015

Figure 9.12 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2016

Figure 9.13 Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.14 Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Figure 9.15 Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.16 Aspen: Historical Revenue ($bn) and AGR (%), 2013-2017

Figure 9.17 Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.18 Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015

Figure 9.19 Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2016-2028

Figure 9.20 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015

Figure 9.21 Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2016-2028

Figure 9.22 Dr. Reddy’s: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017

Figure 9.23 Dr. Reddy’s Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 10.1 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2017

Figure 11.1 Global Generic Drugs Market Forecast: Revenue ($bn), 2017 2022 and 2028